Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease

AstraZeneca

Status: Completed

Conditions: Gastroesophageal Reflux Disease

Study type: Observational

Funder types: Industry

Identifiers

NCT01432392

NIS-GBG-XXX-2011/1

Details and patient eligibility

About

The purpose of this study is to evaluate the impact of gastroesophageal reflux disease (GERD) treatment in primary care setting on symptom control and daily life in symptomatic GERD patients, using both GERD questionnaire and clinical symptoms assessment

Full description

A prospective, observational study to describe symptom control and impact on daily life in patients with gastroesophageal reflux disease (GERD)

Enrollment: 1,000 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients known or newly diagnosed with GERD
• Patients with typical GERD symptoms as heartburn and regurgitation for ≥2 days in the previous week
• Patients, currently not treated with a proton pump inhibitor

Exclusion criteria

• Patients who have been receiving treatment with non-steroidal antiinflammatory drugs within two weeks prior the inclusion in the study
• Patients with medical history of surgery of the esophagus, stomach or duodenum
• Pregnant or nursing females

Trial design

1,000 participants in 1 patient group

1